Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes, Cancer, vol.121, pp.589-97, 2015. ,
Treatment with the radiolabeled somatostatin analog, J Clin Oncol, vol.26, pp.2124-2154, 2008. ,
Nomenclature and classification of neuroendocrine neoplasms of the digestive system, WHO classification of tumours of the digestive system, pp.13-17, 2010. ,
Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer, J Nucl Med, vol.37, pp.1468-72, 1996. ,
Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma, J Nucl Med, vol.53, pp.1863-71, 2012. ,
Are G3 ENETS neuroendocrine neoplasms heterogeneous?, Endocr Relat Cancer, vol.20, pp.649-57, 2013. ,
Performance of (18)fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 (?10%) well-differentiated endocrine carcinoma staging, J Clin Endocrinol Metab, vol.96, pp.665-71, 2011. ,
Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1, Tyr3-octreotate) and 18F-FDG, Cancer, vol.112, pp.2447-55, 2008. ,
Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours, Eur J Nucl Med Mol Imaging, vol.40, pp.881-889, 2013. ,
)F-FDG PET/CT can be used to detect non-functioning pancreatic neuroendocrine tumors, Int J Oncol, vol.45, issue.18, pp.1531-1537, 2014. ,
The role of combined Ga-DOTANOC and (18)FDG PET/CT in the management of patients with pancreatic neuroendocrine tumors, Neuroendocrinology, vol.100, pp.293-302, 2014. ,
Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors, J Clin Oncol, vol.26, pp.963-70, 2008. ,
,
, Techniques de médecine nucléaire pour l'imagerie et le traitement des tumeurs neuroendocrines gastro-entéro-pancréatiques
Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by 18F-FDG PET: feasibility of a metabolic grading system, J Nucl Med, vol.55, pp.1260-1266, 2014. ,
Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors, J Nucl Med, vol.50, pp.858-64, 2009. ,
High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation, J Nucl Med, vol.55, pp.1786-90, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01132696
18F-FDOPA: a multipletarget molecule, J Nucl Med, vol.50, pp.1915-1923, 2009. ,
EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma, Eur J Nucl Med Mol Imaging, vol.39, pp.1977-95, 2012. ,
Staging of carcinoid tumours with 18F-DOPA PET: a prospective, diagnostic accuracy study, Lancet Oncol, vol.7, pp.728-762, 2006. ,
Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors?, J Nucl Med, vol.47, pp.1455-62, 2006. ,
18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type, Eur J Nucl Med Mol Imaging, vol.40, pp.943-66, 2013. ,
Impact of fluorodihydroxyphenylalanine-18F positron emission tomography on management of adult patients with documented or occult digestive endocrine tumors, J Clin Endocrinol Metab, vol.94, pp.1295-301, 2009. ,
18F-fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation, J Nucl Med, vol.55, pp.367-72, 2014. ,
Total 18F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour, Eur J Nucl Med Mol Imaging, vol.38, pp.1854-61, 2011. ,
The value of radiologic interventions and (18)F-DOPA PET in diagnosing and localizing focal congenital hyperinsulinism: systematic review and meta-analysis, Mol Imaging Biol, vol.15, pp.97-105, 2013. ,
18F-FDOPA PET/CT imaging of insulinoma revisited, Eur J Nucl Med Mol Imaging, vol.42, pp.409-427, 2015. ,
Premedication with carbidopa masks positive finding of insulinoma and beta-cell hyperplasia in [18F]-dihydroxy-phenyl-alanine positron emission tomography, J Clin Oncol, vol.26, pp.5307-5315, 2008. ,
Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours, Eur J Nucl Med Mol Imaging, vol.35, pp.1431-1439, 2008. ,
Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours, Eur J Nucl Med Mol Imaging, vol.36, pp.765-70, 2009. ,
Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients, Eur J Nucl Med, vol.20, pp.716-747, 1993. ,
111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging, Eur J Nucl Med Mol Imaging, vol.37, pp.1441-1449, 2010. ,
68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT, J Nucl Med, vol.48, pp.508-526, 2007. ,
Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours, Eur J Nucl Med Mol Imaging, vol.37, issue.68, pp.722-729, 2010. ,
Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis, Eur J Nucl Med Mol Imaging, vol.40, pp.1770-80, 2013. ,
Impact of 68Ga-DOTATATE PET/CT on the surgical management of primary neuroendocrine tumors of the pancreas or ileum, Ann Surg Oncol, vol.22, pp.164-71, 2015. ,
Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours, Eur Radiol, vol.21, pp.2408-2424, 2011. ,
Comparison of abdominal MRI with diffusion-weighted imaging to 68Ga-DOTATATE PET/CT in detection of neuroendocrine tumors of the pancreas, Eur J Nucl Med Mol Imaging, vol.40, pp.897-907, 2013. ,
Evaluation of (68)Ga-DOTANOC PET/CT imaging in a large exclusive population of pancreatic neuroendocrine tumors, Abdom Imaging, vol.40, pp.299-309, 2015. ,
Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study, J Clin Endocrinol Metab, vol.88, pp.5353-60, 2003. ,
Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas, J Nucl Med, vol.52, pp.1073-1081, 2011. ,
Diagnostic performance of somatostatin receptor PET/CT using 68Ga-DOTANOC in gastrinoma patients with negative or equivocal CT findings, Abdom Imaging, vol.38, pp.552-60, 2013. ,
Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT, Eur J Nucl Med Mol Imaging, vol.37, pp.67-77, 2010. ,
68Ga-DOTANOC PET/CT in patients with carcinoma of unknown primary of neuroendocrine origin, Clin Nucl Med, vol.37, pp.245-51, 2012. ,
Ga-DOTATATE PET/CT in the evaluation of patients with neuroendocrine metastatic carcinoma of unknown origin, Ann Nucl Med, vol.28, issue.68, pp.638-683, 2014. ,
Diagnostic value of (68)Ga-DOTATATE PET/CT in liver metastases of neuroendocrine tumours of unknown origin, Nucl Med Mol Imaging, vol.48, pp.212-217, 2014. ,
68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors, J Nucl Med, vol.51, pp.669-73, 2010. ,
Comparison of the prognostic values of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in patients with well-differentiated neuroendocrine tumor, Eur J Nucl Med Mol Imaging, vol.41, pp.2194-202, 2014. ,
Clinical radioimmunotherapy-the role of radiobiology, Nat Rev Clin Oncol, vol.8, pp.8720-8754, 2011. ,
Apoptosis and p53 are not involved in the anti-tumor efficacy of 125 Ilabeled monoclonal antibodies targeting the cell membrane, Nucl Med Biol, vol.40, pp.471-80, 2013. ,
URL : https://hal.archives-ouvertes.fr/inserm-00815724
What is the role of the bystander response in radionuclide therapies?, Front Oncol, vol.3, p.215, 2013. ,
MIRD continuing education: bystander and low dose-rate effects: are these relevant to radionuclide therapy?, J Nucl Med, vol.48, pp.1683-91, 2007. ,
Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients, Cancer, vol.101, pp.1987-93, 2004. ,
Phase I study of peptide receptor radionuclide therapy with, Semin Nucl Med, vol.32, pp.110-132, 2002. ,
Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0, Tyr3] octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors, Semin Nucl Med, vol.36, pp.147-56, 2006. ,
177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study, Eur J Nucl Med Mol Imaging, vol.41, pp.1845-51, 2014. ,
Favourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumours ,
, Eur J Nucl Med Mol Imaging, vol.42, pp.176-85, 2015.
Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy, Eur J Nucl Med Mol Imaging, vol.41, pp.223-253, 2014. ,
Kwekkeboom DJ. Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0, Tyr3] octreotate, J Nucl Med, vol.52, pp.1361-1369, 2011. ,
Peptides and receptors in imageguided therapy: theranostics for neuroendocrine neoplasms, Semin Nucl Med, vol.42, pp.190-207, 2012. ,
Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors, Eur J Nucl Med Mol Imaging, vol.35, pp.1847-56, 2008. ,
Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors, Eur J Nucl Med Mol Imaging, vol.42, pp.5-19, 2015. ,
Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy, Eur J Nucl Med Mol Imaging, vol.38, pp.459-66, 2011. ,
PRRT as neoadjuvant treatment in NET, Recent Results Cancer Res, vol.194, pp.479-85, 2013. ,
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1. 1), Eur J Cancer, vol.45, pp.228-275, 2009. ,
From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors, J Nucl Med, vol.50, pp.122-50, 2009. ,
18F-FDG PET predicts survival after pretargeted radioimmunotherapy in patients with progressive metastatic medullary thyroid carcinoma, Eur J Nucl Med Mol Imaging, vol.41, pp.1501-1511, 2014. ,
68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors, J Nucl Med, vol.51, pp.1349-56, 2010. ,
, Pour en savoir plus
Radiopharmaceutiques à visée thérapeutique : indications, précautions d'emploi et principaux résultats. EMC Radiologie et imagerie médicale : principes et techniques -Radioprotection, 2013. ,
, Thésaurus national de cancérologie digestive : www.tncd.Org
MD (catherine.ansquer@chu-nantes.fr) ,
, Inserm UMR892, 8, quai Moncousu, BP 70721, 44007 Nantes cedex, France. F. Kraeber-Bodéré, MD, PhD. Service de médecine nucléaire, Centre hospitalier universitaire Hôtel-Dieu, 1, place Alexis-Ricordeau, 44093 Nantes cedex 1, France. Centre régional de recherche en cancérologie Nantes/Angers (CRCNA), EMC -Radiologie et imagerie médicale -abdominale -digestive, vol.11, issue.3, pp.1-11, 2016.